Mechanism of Activation of Triciribine Phosphate (TCN-P) As a Prodrug Form of TCN
Overview
Affiliations
The tricyclic nucleotide triciribine phosphate (TCN-P) was synthesized as a water-soluble derivative of the tricyclic nucleoside TCN (L. B. Townsend et al, INSERM 81:37, 1978). Growth of L1210 cells in vitro was inhibited equally by TCN and TCN-P. A requirement for adenosine kinase activity for activation of both TCN and TCN-P was established by the observation that growth inhibition by either compound was decreased 200-fold by the adenosine kinase inhibitor 5-iodotubercidin and greater than 5000-fold in L1210/T, an adenosine kinase-deficient subline. The TCN/TCN-P resistance of L1210/T cells was correlated with lack of formation of intracellular TCN-P from either TCN or TCN-P. Thus, it appeared that TCN-P was hydrolyzed to TCN and then rephosphorylated intracellularly. Both the horse serum-containing culture medium and the intact cells possessed nucleotide phosphatase activity, which may contribute to the hydrolysis of TCN-P to TCN in the L1210 cell cultures. The requirement for hydrolysis of TCN-P to TCN for formation of intracellular TCN-P from exogenous TCN-P was also shown directly by the observation that human erythrocytes, which lack ectophosphatases, readily formed intracellular TCN-P from TCN but not from TCN-P when incubated in buffer.
Shan S, Liu F, Ford E, Caldwell R, Narayanan S, Somanath P Biomed Pharmacother. 2023; 162:114714.
PMID: 37080089 PMC: 10208444. DOI: 10.1016/j.biopha.2023.114714.
Adil M, Verma A, Rudraraju M, Narayanan S, Somanath P J Cell Physiol. 2021; 236(9):6597-6606.
PMID: 33624300 PMC: 8014085. DOI: 10.1002/jcp.30343.
Proteome activity landscapes of tumor cell lines determine drug responses.
Frejno M, Meng C, Ruprecht B, Oellerich T, Scheich S, Kleigrewe K Nat Commun. 2020; 11(1):3639.
PMID: 32686665 PMC: 7371697. DOI: 10.1038/s41467-020-17336-9.
Triciribine increases LDLR expression and LDL uptake through stabilization of LDLR mRNA.
Bjune K, Wierod L, Naderi S Sci Rep. 2018; 8(1):16174.
PMID: 30385871 PMC: 6212527. DOI: 10.1038/s41598-018-34237-6.
Nayar U, Sadek J, Reichel J, Hernandez-Hopkins D, Akar G, Barelli P J Clin Invest. 2017; 127(6):2066-2080.
PMID: 28504647 PMC: 5451239. DOI: 10.1172/JCI83936.